If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
=== Clinical trials === Human trials began on January 26, 2021, with 60 volunteers between the ages of 18 and 65 in Toronto. Of these, 15 would receive a placebo and three groups of 15 would receive different doses of the vaccine. The volunteers will be monitored for 13 months. The company said that enough data would be available in May which could result in a Phase 2 clinical testing beginning soon after that, pending regulatory approval. If the results of a subsequent larger human trial are positive, the vaccine could enter a commercialization phase in 2022. The Phase 1 clinical trial lead was Piyush Patel. At the 29 April meeting with the House of Commons, Sorenson estimated that PTX-COVID19-B could be approved by Health Canada by "January or February 2022".
== Current Appointments and Affiliations == At MIT, Bhatia is the John J. and Dorothy Wilson Professor at both the Institute for Medical Engineering & Science (IMES) and the Department of Electrical Engineering & Computer Science (EECS). She serves as the Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research and is an Investigator of the Howard Hughes Medical Institute. Her affiliations also extend to being an Institute Member of the Broad Institute and an Associate Faculty at the Wyss Institute for Biologically Inspired Engineering. Beyond her research and academic roles, Bhatia is the Founding Director of the MIT Faculty Founder Initiative. This initiative is dedicated to increasing the representation of MIT faculty members, particularly women, who launch biotechnology companies, addressing a significant gender gap in biotech entrepreneurship. Bhatia has been a member of Brown University's board of trustees since 2015, serving as a fellow since 2019 and as chair of academic affairs currently. She serves on the board of directors at Vertex Pharmaceuticals, where she chairs the science and technology committee. She has presented on the application of engineering approaches to medical problems at events including the World Economic Forum, TED, the Bill & Melinda Gates Foundation's Grand Challenges, and the Cancer Moonshot.
Lorenzo Feritta, who at the time was one of the presidents of the UFC, said, "We want 100 percent of the fighters tested the night they compete". Also, in addition to the drug testing protocols in place for competitors on fight night, the UFC conducts additional testing for main event fighters or any fighters that are due to compete in championship matches. This includes enhanced, random 'out of competition' testing for performance-enhancing drugs, with both urine and blood samples being taken. The UFC also announced that all potential UFC signees would be subject to mandatory pre-contract screening for performance-enhancing drugs prior to being offered a contract with the promotion.
Sources: en.wikipedia.org
=== Approval === On April 1, 2008, Progenics and Wyeth announced that Health Canada has approved methylnaltrexone for the treatment of opioid-induced constipation. It was later approved by the US FDA on April 24, 2008.
have disease progression during or following platinum-containing chemotherapy. have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. On 16 February 2018, the Food and Drug Administration approved durvalumab for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Temperature If the relative humidity is kept constant, the higher the temperature, the higher the drying rate. Temperature influences the drying rate by increasing the moisture holding capacity of the air, as well as by accelerating the diffusion rate of moisture through the wood. The actual temperature in a drying kiln is the dry-bulb temperature (usually denoted by Tg), which is the temperature of a vapour-gas mixture determined by inserting a thermometer with a dry bulb. On the other hand, the wet-bulb temperature (TW) is defined as the temperature reached by a small amount of liquid evaporating in a large amount of an unsaturated air-vapour mixture. The temperature sensing element of this thermometer is kept moist with a porous fabric sleeve (cloth) usually put in a reservoir of clean water. A minimum air flow of 2 m/s is needed to prevent a zone of stagnant damp air formation around the sleeve. Since air passes over the wet sleeve, water is evaporated and cools the wet-bulb thermometer. The difference between the dry-bulb and wet-bulb temperatures, the wet-bulb depression, is used to determine the relative humidity from a standard hygrometric chart. A higher difference between the dry-bulb and wet-bulb temperatures indicates a lower relative humidity. For example, if the dry-bulb temperature is 100 °C and wet-bulb temperature 60 °C, then the relative humidity is read as 17% from a hygrometric chart.
Sources: en.wikipedia.org
As with other hallucinogens, these substances are often taken for the purposes of facilitating spiritual processes, mental reflection or recreation. Some research chemicals on the market were not psychoactive, but can be used as precursors in the synthesis of other potentially psychoactive substances, for example, 2C-H, which could be used to make 2C-B and 2C-I among others. Extensive surveys of structural variations have been conducted by pharmaceutical corporations, universities and independent researchers over the last century, from which some of the presently available research chemicals derive. One particularly notable researcher is Alexander Shulgin, who presented syntheses and pharmacological explorations of hundreds of substances in the books TiHKAL and PiHKAL (co-authored with Ann Shulgin), and served as an expert witness for the defense in several court cases against manufacturers of psychoactive drugs. The majority of chemical suppliers sold research chemicals in bulk form as powder, not as pills, as selling in pill form would invalidate the claims that they were being sold for non-consumptive research. Active dosages vary widely from substance to substance, ranging from micrograms to hundreds of milligrams, but while it is critical for the end user to weigh doses with a precision scale, instead of guessing ("eyeballing"), many users did not do this and this led to many emergency room visits and several deaths, which were a prominent factor leading to the emergency scheduling of several substances and eventually Operation Web Tryp.
It may replace glucose in many chemical reactions due to its similarity in structure, may prevent the non-enzymatic glycosylation of proteins, and might reduce glycated hemoglobin (HbA1c) levels. Secondly, vitamin C has also been suggested to play a role in lipid regulation as a controlling catabolism of cholesterol to bile acid.
== Competitions == The ARL controls the National Rugby League and NRL Women's Premiership as well as annual representative competitions such as the State of Origin series, the Indigenous All Stars Match, the Affiliated States Championship and the Women's National Championships. The ARL previously ran the National Youth Competition. This competition, which was for male players Under 20 years of age, was replaced in 2018 by state-run competitions. The New South Wales Rugby League run the Jersey Flegg Cup for male Under 21 players. The Queensland Rugby League run the Mal Meninga Cup for male Under 18 players, with players Under 21 that are outside NRL squads playing for clubs in the open-age Queensland Cup.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.